Skip to main content

Advertisement

SpringerLink
Log in

Dopamine agonist-based strategies in the treatment of Parkinson’s disease

  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

More therapeutic options have become available for Parkinson’s disease (PD) in recent years, leading to significant improvements in motor control both at early and advanced disease stages. More importantly, the need to expand disease management beyond motor symptom control has been recently highlighted and contribution of non-motor features to quality of life is now relevant. Dopamine agonists represent a valid therapeutic option in PD and their effect on non-motor domains like mood or cognition is now acknowledged as a key factor in fully addressing patients’ needs. Pramipexole is a well established dopamine agonist that is currently being investigated for its potential disease-modifying effect and action on mood in PD. In this review we will examine factors contributing to treatment decision-making and discuss how a proper balance between motor and non-motor features should be aimed for in approaching PD therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Quinn N, Critchley P, Marsden CD (1987) Young onset Parkinson’s disease. Mov Disord 2:73–91

    Article  PubMed  CAS  Google Scholar 

  2. Schrag A, Ben-Shlomo Y, Brown R et al (1998) Young onset Parkinson’s disease revisited — clinical features, natural history, and mortality. Mov Disord 13:885–894

    Article  PubMed  CAS  Google Scholar 

  3. Hristova AH (2000) Early Parkinson’s disease: what is the best approach to treatment? Drugs Aging 17:165–181

    Article  PubMed  CAS  Google Scholar 

  4. Grosset D, Taurah L, Burn DJ et al (2007) A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson’s disease left untreated at diagnosis. J Neurol Neurosurg Psychiatry 78:465–469

    Article  PubMed  CAS  Google Scholar 

  5. Fahn S, Oakes D, Shoulson I et al (2004) Levodopa and the progression of Parkinson’s disease. N Engl J Med 351:2498–2508

    Article  PubMed  CAS  Google Scholar 

  6. Antonini A (2007) Continuous dopaminergic stimulation — From theory to clinical practice. Parkinsonism Relat Disord 13[Suppl]:S24–S28

    Article  PubMed  Google Scholar 

  7. Kondo T (2002) Initial therapy for Parkinson’s disease: levodopa vs. dopamine receptor agonists. J Neurol 249[Suppl 2]:II25–II29

    PubMed  Google Scholar 

  8. Suchowersky O, Reich S, Perlmutter J et al (2006) Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review) of the American Academy of Neurolology. Neurology 66:968–975

    Article  PubMed  CAS  Google Scholar 

  9. Rinne UK, Bracco F, Chouza C et al (1998) Early treatment of Parkinson’s disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 55[Suppl 1]:23–30

    Article  PubMed  CAS  Google Scholar 

  10. Rascol O, Brooks DJ, Korczyn AD et al (2000) A five year study of the incidence of dyskinesia in patients with early Parkinson’s disease who where treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342:1484–1491

    Article  PubMed  CAS  Google Scholar 

  11. The Parkinson Study Group (2002) Pramipexole vs Levodopa as initial treatment for Parkinson Disease. A randomized controlled study. JAMA 5:1653–1661

    Article  Google Scholar 

  12. Antonini A, Poewe W (2007) Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson’s disease. Lancet Neurol 6:826–829

    Article  PubMed  CAS  Google Scholar 

  13. Parkinson Study Group (2002) A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol 59:1937–1943

    Article  Google Scholar 

  14. Chaudhuri RK, Healy D, Shapira HV et al (2006) Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol 5:235–245

    Article  PubMed  Google Scholar 

  15. Antonini A, Colosimo C, Marconi R et al (2008) The PRIAMO study: background, methods and recruitment. Neurol Sci 29:61–65

    Article  PubMed  Google Scholar 

  16. Antonini A (2008) Unravelling depression in Parkinson’s disease. Eur J Neurol 15:885–886

    Article  PubMed  CAS  Google Scholar 

  17. Kulisevsky J, Pascual-Sedano B, Barbanoj M et al (2007) Acute effects of immediate and controlled-release levodopa on mood in Parkinson’s disease: a double-blind study. Mov Disord 22:62–67

    Article  PubMed  Google Scholar 

  18. Lemke MR, Brecht HM, Koester J, Reichmann H (2006) Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson’s disease. J Neurol Sci 248:266–270

    Article  PubMed  CAS  Google Scholar 

  19. Barone P, Scarzella L, Marconi R et al and the Depression/Parkinson Italian Study Group (2006) Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease: a national multicenter parallel-group randomized study. J Neurol 253:601–607

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Istituti Clinici di Perfezionamento, Parkinson Institute, Via Bignami 1, Milan, Italy

    Angelo Antonini

  2. Department of Neurology, University of Naples, Naples, Italy

    Paolo Barone

Authors
  1. Angelo Antonini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paolo Barone
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Angelo Antonini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Antonini, A., Barone, P. Dopamine agonist-based strategies in the treatment of Parkinson’s disease. Neurol Sci 29 (Suppl 5), 371–374 (2008). https://doi.org/10.1007/s10072-008-1049-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-008-1049-4

Keywords

Search

Navigation